Coronary Artery Disease: What Every Patient Should Know

I spend more time talking about coronary artery disease than any other topic in my cardiology practice. It's the most common form of heart disease in the United States, and it remains the leading cause of death for both men and women. Yet most patients I see have only a vague understanding of what it actually is, how it develops, and what we can do about it. Some come in after a family member's heart attack, anxious and wanting answers. Others find out they have it during a routine workup, completely blindsided because they felt fine. And a meaningful number of patients walk through my door believing coronary artery disease is an inevitable consequence of aging, something you can't do much about. That's simply not true.

Coronary artery disease, often abbreviated CAD, is a condition where the arteries that supply blood to your heart muscle become narrowed or blocked by a gradual buildup of fatty deposits called plaque. That process is called atherosclerosis. It doesn't happen overnight. It develops over years and decades, driven by a combination of risk factors that we understand well and, in most cases, can modify. The consequences of CAD range from chest pain with exertion (what we call stable angina) to a full-blown heart attack, where part of the heart muscle dies because its blood supply is suddenly cut off.

The reason I'm writing this article is that understanding coronary artery disease gives you power over it. When you understand what's happening inside your arteries, you can make informed decisions about your lifestyle, your medications, and your treatment options. You can have more productive conversations with your cardiologist. And you can take action before something serious happens, rather than reacting after the fact.

How Coronary Artery Disease Develops

Your coronary arteries are the blood vessels that wrap around the outside of your heart and deliver oxygen-rich blood to the heart muscle. You have two main coronary arteries, the left and the right, and they branch into smaller vessels that reach every part of the heart. When these arteries are healthy and wide open, blood flows freely and your heart gets all the oxygen it needs, whether you're sitting at your desk or running up a flight of stairs.

Coronary artery disease begins with damage to the inner lining of these arteries, a layer called the endothelium. This damage can be caused by high blood pressure, high cholesterol, smoking, diabetes, or chronic inflammation. Once the endothelium is injured, cholesterol particles, particularly low-density lipoprotein (LDL), begin to accumulate in the arterial wall beneath the lining. Your immune system recognizes these deposits as a problem and sends white blood cells to clean them up. But instead of resolving the issue, these immune cells become trapped, engorged with cholesterol, and transform into what we call foam cells. This triggers a chronic inflammatory response.

Over time, this process creates a plaque: a mix of cholesterol, immune cells, calcium, and fibrous tissue sitting inside the artery wall. The plaque grows slowly, narrowing the artery's internal channel. In some cases, the artery initially compensates by expanding outward, a process called positive remodeling, which can mask the disease from detection on standard tests. Eventually, though, the plaque encroaches on the space where blood flows, reducing the amount of oxygen that can reach the heart muscle during periods of increased demand.

What makes this process particularly dangerous is that plaques aren't all the same. Some are stable: they have a thick fibrous cap covering the cholesterol core, and they grow slowly over years. These tend to cause predictable symptoms during exertion. Other plaques are vulnerable: they have thin caps, large cholesterol pools, and active inflammation. These vulnerable plaques can rupture suddenly, even when they aren't causing significant narrowing. When a plaque ruptures, the body forms a blood clot at the site, and that clot can partially or completely block the artery within minutes. This is the mechanism behind most heart attacks.

Research published in JAMA has confirmed that most acute coronary events arise from plaques causing less than 70% stenosis, plaques that were previously non-flow-limiting. This means a heart attack can happen in an artery that didn't look particularly concerning on a previous test. It's a humbling reality, and it's why I emphasize aggressive risk factor management for all of my patients with any degree of atherosclerosis, not just those with severe blockages.

Risk Factors: What Puts You at Risk

Understanding your risk factors is the first step toward prevention. Some you can change, and some you can't, but knowing where you stand allows us to build a strategy.

Modifiable risk factors are the ones you and I can work on together. High blood pressure damages the arterial lining and accelerates plaque formation. High LDL cholesterol provides the raw material for plaque. Diabetes worsens atherosclerosis through multiple pathways including insulin resistance, inflammation, and damage to the blood vessel walls. Smoking is one of the most potent accelerators of coronary artery disease; it injures the endothelium, raises LDL, lowers HDL, promotes blood clotting, and triggers arterial spasm. Obesity, especially visceral (belly) fat, is strongly linked to insulin resistance, inflammation, and an unfavorable cholesterol profile. Physical inactivity independently increases your risk, and each metabolic equivalent (MET) of cardiorespiratory fitness you achieve reduces your incidence of CAD by roughly 20%. Chronic stress and poor diet round out the list of factors within your control.

Non-modifiable risk factors include age (risk increases significantly for men at age 45 and women at age 55), male sex (though women catch up after menopause), and family history of premature CAD (a first-degree male relative affected before age 55, or a female relative before age 65).

There are also emerging risk factors that researchers are paying increasing attention to: lipoprotein(a), a genetically determined particle that accelerates plaque formation; metabolic syndrome, a cluster of insulin resistance, high triglycerides, low HDL, elevated blood pressure, and excess belly fat; chronic inflammatory conditions like rheumatoid arthritis and lupus; chronic kidney disease; sleep apnea; and even clonal hematopoiesis, a recently discovered condition where mutations in blood stem cells promote vascular inflammation.

The heritability of fatal coronary artery disease approaches 50%, with genome-wide studies identifying hundreds of genetic variants that contribute to risk. This means that even if you do everything right with your lifestyle, your genetic background plays a significant role. But it also means that if your genetics put you at higher risk, the lifestyle and medical interventions we have are even more valuable, because you have more to gain from them.

Symptoms: Stable Angina and Acute Coronary Syndromes

Coronary artery disease presents along a spectrum, from no symptoms at all to a life-threatening emergency. Understanding where you fall on this spectrum, and recognizing warning signs, can save your life.

Stable angina is the most common symptom of chronic CAD. It typically presents as chest pressure, heaviness, tightness, or squeezing that occurs with physical exertion or emotional stress and resolves within minutes of resting or taking nitroglycerin. The pattern is predictable: the same activities tend to trigger the same symptoms, and the symptoms have been consistent over weeks to months. Some patients describe it as chest discomfort rather than pain. Others feel it in their jaw, neck, shoulders, arms, or upper back. I always ask patients about exertional breathlessness, because in many people, particularly women and patients with diabetes, shortness of breath during activity is the primary symptom rather than chest pain.

Acute coronary syndromes (ACS) represent the dangerous end of the spectrum. ACS occurs when a plaque ruptures or erodes, forming a blood clot that suddenly reduces or blocks blood flow. There are three types:

ST-elevation myocardial infarction (STEMI) accounts for about 30% of ACS cases. It means the coronary artery is completely blocked, and the heart muscle supplied by that artery is actively dying. The ECG shows characteristic ST-segment elevation. STEMI is a true medical emergency that requires immediate reperfusion, either through emergency catheterization and stenting (primary PCI) or, when that's not available quickly enough, clot-dissolving medications.

Non-ST-elevation myocardial infarction (NSTEMI) is the most common type of ACS. The artery is partially blocked, and the heart muscle is being injured but the blockage isn't complete. Blood tests show elevated troponin, a protein released when heart cells are damaged. Treatment depends on the patient's risk level and typically involves urgent catheterization within 24 hours.

Unstable angina has the same presentation as NSTEMI, with chest pain at rest or with minimal exertion, but troponin levels remain normal. It's a warning that a heart attack may be imminent and requires urgent evaluation.

About 79% of men and 74% of women with ACS present with chest discomfort, but roughly 40-48% have what we consider atypical symptoms: isolated shortness of breath, nausea, fatigue, dizziness, or pain in locations other than the chest. Women, older adults, and patients with diabetes are more likely to have atypical presentations. If something feels wrong, get evaluated. I would much rather have you come to the emergency room for indigestion than stay home having a heart attack.

Diagnostic Workup: How We Find and Evaluate CAD

The approach to diagnosing coronary artery disease depends on whether we're evaluating a stable patient with possible chronic CAD or someone presenting with acute symptoms.

For stable patients with chest pain or suspected CAD, the 2021 ACC/AHA Chest Pain Guidelines recommend a risk-stratified approach. This means we first assess your overall probability of having significant CAD based on your symptoms, risk factors, age, and sex, and then choose the most appropriate test.

Coronary CT angiography (CCTA) has emerged as a first-line test for patients with low-to-intermediate risk. It's a non-invasive scan that creates detailed images of your coronary arteries using CT technology and an intravenous contrast dye. CCTA has excellent sensitivity (over 90%) and a very high negative predictive value, meaning that if the scan is clean, you almost certainly don't have significant blockages. Just as importantly, CCTA can identify non-obstructive plaque, the early disease that doesn't yet cause symptoms but does indicate elevated risk. The PROMISE trial found that over half of cardiovascular events occurred in patients who had non-obstructive disease, reinforcing the value of identifying and treating atherosclerosis early.

Stress testing remains an important tool, especially for assessing whether blockages are actually limiting blood flow. Options include exercise ECG testing (sensitivity 68%, specificity 77%), stress echocardiography (sensitivity 80-85%, specificity 84-86%), nuclear perfusion imaging with SPECT (sensitivity 88%, specificity 75%), and stress cardiac MRI or PET scanning, which offer the highest accuracy. When a patient can exercise, I prefer exercise-based testing because it provides functional and prognostic information: how much you can do, what your heart rate response looks like, whether you develop symptoms or ECG changes, and how quickly you recover.

Invasive coronary angiography (cardiac catheterization) is reserved for patients who are high risk, who have concerning findings on non-invasive testing, or who are being considered for revascularization. During catheterization, we thread a thin catheter through an artery (usually the wrist) to the heart and inject contrast dye directly into the coronary arteries, producing real-time X-ray images. When we find a blockage that appears moderate, we can measure its functional significance using fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR). These measurements tell us whether a blockage is actually restricting blood flow enough to warrant treatment. An FFR of 0.80 or lower, or an iFR of 0.89 or lower, indicates a hemodynamically significant lesion.

For patients presenting with acute coronary syndromes, the approach is different and more urgent. An ECG should be obtained within 10 minutes of arrival. High-sensitivity troponin blood tests are drawn immediately and repeated at intervals to detect heart muscle injury. STEMI patients go directly to the catheterization lab for emergency intervention. NSTEMI patients undergo urgent risk stratification and typically proceed to catheterization within 24 hours.

Treatment: The Foundation of Medical Therapy

The treatment of coronary artery disease has evolved dramatically over the past two decades, and the evidence is clear: for most patients with stable CAD, optimal medical therapy is the foundation of treatment. The 2023 AHA/ACC Guidelines for the Management of Patients with Chronic Coronary Disease provide the current framework.

Lipid management is the cornerstone. High-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) is recommended for all patients with established CAD, with a goal of reducing LDL cholesterol by at least 50%. Statins do far more than lower cholesterol: they stabilize plaques, reduce inflammation, and improve endothelial function. For patients who don't reach their LDL goal on a statin alone, or who can't tolerate statins, we have powerful adjunctive options. Ezetimibe blocks cholesterol absorption in the gut and reduces events when added to a statin. PCSK9 inhibitors (evolocumab and alirocumab) are injectable medications given every two to four weeks that can reduce LDL by an additional 50-60% and have been shown to reduce cardiovascular events by 15-17%. Inclisiran is a newer approach using small interfering RNA (siRNA) to silence the gene that produces PCSK9, requiring injections only twice yearly. Bempedoic acid is an oral option that reduces MI and revascularization in statin-intolerant patients.

Blood pressure control targets less than 130/80 mmHg. I typically start with ACE inhibitors or ARBs, especially in patients with diabetes, kidney disease, or reduced heart function. Beta-blockers are appropriate for patients with a recent heart attack or ongoing angina. Calcium channel blockers and thiazide diuretics are effective alternatives or additions when needed.

Antiplatelet therapy with aspirin is standard for secondary prevention in patients with established CAD. After a heart attack or stent placement, dual antiplatelet therapy (DAPT) combining aspirin with a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) is used for a period that we individualize based on the balance between bleeding risk and ischemic risk. Current evidence supports shorter DAPT durations of 3-6 months in many situations, particularly in patients at higher bleeding risk.

Antianginal medications control chest pain symptoms. Beta-blockers and calcium channel blockers are first-line. An important update from the 2023 guidelines: long-term beta-blocker therapy is no longer recommended for stable CAD patients who haven't had a recent heart attack (within the past year) and who have normal heart function. This is a significant shift from previous practice. Additional options for persistent angina include long-acting nitrates, ranolazine, and ivabradine.

Diabetes management in patients with CAD now prioritizes medications with proven cardiovascular benefits. SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce heart failure hospitalizations and slow kidney disease progression. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) reduce heart attacks, strokes, and cardiovascular death. These agents are recommended for patients with CAD and diabetes, and in select patients even without diabetes.

Lifestyle interventions remain powerful medicine. Cardiac rehabilitation reduces both morbidity and mortality and should be prescribed for all patients after a heart attack, stent, or bypass surgery. Regular physical activity, a heart-healthy diet (Mediterranean-style eating has the strongest evidence), smoking cessation, weight management, and stress reduction are foundational.

The ISCHEMIA Trial: A Landmark in CAD Management

The ISCHEMIA trial was one of the most important cardiology studies of the past decade, and it fundamentally changed how I counsel patients about their treatment options for stable coronary artery disease.

ISCHEMIA enrolled 5,179 patients with stable CAD and moderate-to-severe ischemia on stress testing. Half were randomized to an invasive strategy (cardiac catheterization followed by revascularization with PCI or CABG when feasible) and half to a conservative strategy (optimal medical therapy alone, with catheterization reserved for failure of medical management).

The results were striking. At 3.3 years of follow-up, there was no difference in the primary composite endpoint of cardiovascular death, myocardial infarction, hospitalization for unstable angina, heart failure, or cardiac arrest (hazard ratio 0.93, 95% confidence interval 0.80-1.08). There was no difference in cardiovascular death or all-cause death.

What the invasive strategy did provide was better angina relief. Patients who underwent revascularization had greater improvement in chest pain symptoms, and this benefit was most pronounced in patients who had angina on a daily or weekly basis. The symptom benefit was sustained through 36 months.

There was also an important nuance in the myocardial infarction data. The invasive strategy was associated with an early increase in periprocedural MI (heart attacks related to the procedure itself) but a late reduction in spontaneous MI. These two effects largely offset each other.

What does ISCHEMIA mean for you as a patient? If you have stable coronary artery disease with chest pain that's well controlled on medications, you can feel confident that medical therapy alone is a safe and effective strategy. Proceeding directly to catheterization and stenting is not mandatory and doesn't reduce your risk of dying or having a heart attack compared to medical therapy. However, if your angina is significantly affecting your quality of life despite medications, revascularization offers meaningful symptom improvement. The decision should be a shared one between you and your cardiologist, based on your individual symptoms, preferences, and values.

PCI versus CABG: Choosing the Right Revascularization Strategy

When revascularization is indicated, the choice between percutaneous coronary intervention (PCI, or stenting) and coronary artery bypass graft surgery (CABG) depends on the anatomy and complexity of your disease, your other medical conditions, and your preferences.

CABG is clearly superior in several scenarios. For patients with left main coronary artery disease that is anatomically complex (a SYNTAX score above 33), CABG provides significantly lower rates of major cardiac events and cardiac death at 5 years compared to PCI. For multivessel disease with high anatomic complexity, PCI is associated with approximately 40% higher mortality at 10 years compared to CABG. For diabetic patients with multivessel disease, the FREEDOM trial demonstrated that CABG reduces mortality compared to PCI. And for patients with significantly reduced heart function (ejection fraction 35% or below), CABG improves survival.

CABG offers a unique advantage that PCI cannot replicate: field protection. Bypass grafts are sewn to the coronary artery downstream of the disease, effectively protecting the entire territory of that artery from future blockages that may develop upstream. PCI, by contrast, treats only the specific segment where the stent is placed. This is why CABG consistently shows lower rates of spontaneous MI and repeat revascularization compared to PCI.

PCI is a reasonable option for patients with less complex anatomy (left main with SYNTAX score of 33 or below), for patients who are at high surgical risk, and in situations where patient preference after a thorough Heart Team discussion favors a less invasive approach. PCI also has a shorter recovery time and avoids the risks of open-heart surgery.

In older adults (75 years and above), CABG continues to show consistent benefit for left main and multivessel disease, though the decision requires individualized assessment of frailty, comorbidities, cognitive function, and life expectancy.

The key takeaway: the decision between PCI and CABG should be made by a Heart Team, a multidisciplinary group including a cardiologist and a cardiac surgeon, who can evaluate your specific anatomy and clinical situation and present both options honestly.

Emerging Therapies: What's on the Horizon

The field of coronary artery disease treatment is advancing rapidly, and several new approaches are changing how we think about secondary prevention.

Colchicine is the biggest recent development in anti-inflammatory therapy for CAD. This old medication, used for gout for decades, has been repurposed based on compelling trial data. The LoDoCo2 trial showed a 31% reduction in major cardiovascular events in patients with stable CAD taking colchicine 0.5 mg daily. The COLCOT trial demonstrated a 23% reduction in events when started shortly after a heart attack. The benefit is comparable to or greater than what PCSK9 inhibitors provide. Colchicine is now FDA-approved for atherosclerotic cardiovascular disease and is particularly effective in patients with persistent inflammation (elevated high-sensitivity C-reactive protein above 2 mg/L) despite statin therapy. I'm incorporating colchicine into my treatment plans more frequently, though it needs to be used carefully in patients with kidney or liver disease and avoided with certain drug interactions.

The science behind colchicine reflects a broader insight: residual inflammatory risk matters enormously. Research published in the Lancet has shown that elevated hsCRP on statin therapy is a stronger predictor of future cardiovascular events than residual cholesterol risk, and approximately 60% of patients on secondary prevention statins still have hsCRP above 2 mg/L. This means that even after we optimize cholesterol, many patients carry significant risk from ongoing vascular inflammation.

Other anti-inflammatory therapies are in development. Ziltivekimab, an antibody targeting interleukin-6, is being studied in large trials involving patients with chronic kidney disease, heart failure, and acute coronary syndromes. Canakinumab, which targets interleukin-1 beta, showed a 15-17% reduction in events in the CANTOS trial but hasn't been brought to market for cardiovascular indications.

On the lipid front, inclisiran represents a shift toward longer-acting therapies that simplify adherence. Its twice-yearly dosing is a significant advantage for patients who struggle with daily pills or biweekly injections. Icosapent ethyl, a purified EPA omega-3 fatty acid, reduces events in high-risk patients with elevated triglycerides.

In antiplatelet therapy, low-dose rivaroxaban (2.5 mg twice daily) combined with aspirin is now approved for patients with stable CAD to reduce major cardiovascular events, adding an antithrombotic dimension to secondary prevention.

Common Misconceptions About Coronary Artery Disease

"I'd know if I had a blockage." Many patients with significant coronary artery disease have no symptoms at all. The disease can progress silently for years. This is especially true in patients with diabetes, who may have impaired pain sensation. Regular screening and risk factor assessment are the best ways to detect disease before it causes trouble.

"My stress test was normal, so my arteries are fine." A normal stress test means that at the time of the test, we didn't detect flow-limiting ischemia. It doesn't mean your arteries are free of plaque. Many heart attacks occur from rupture of plaques that weren't causing significant narrowing. That's why coronary CT angiography, which can visualize plaque directly, has become such a valuable tool.

"I need a stent to fix my blockage." The ISCHEMIA trial showed that for stable CAD, stenting doesn't reduce the risk of death or heart attack compared to medical therapy alone. Stents are excellent for relieving symptoms that aren't controlled with medications, and they're lifesaving in the setting of a heart attack. But for stable disease, they're a symptom treatment, not a cure.

"Once I have a stent, I'm fixed." A stent treats one spot in one artery. Atherosclerosis is a diffuse disease affecting your entire arterial system. Without aggressive risk factor management, new blockages will develop in other locations. Medical therapy, particularly statins, antiplatelet agents, and lifestyle changes, protects your entire vascular system. The stent only protects the few centimeters where it sits.

"Bypass surgery means my heart disease is cured." Similar to stents, bypass grafts address specific segments of disease. They can last many years, especially arterial grafts, but the underlying process of atherosclerosis continues if risk factors aren't controlled. Every patient after CABG needs lifelong medical therapy and lifestyle management.

Managing Your Expectations

If you've been diagnosed with coronary artery disease, here's what I want you to know about the road ahead.

First, this is a chronic condition that requires ongoing management. There's no single procedure or medication that makes it go away. But with the tools we have today, the vast majority of patients with CAD live long, active, fulfilling lives.

Second, medical therapy works. The combination of statins, blood pressure control, antiplatelet therapy, and lifestyle modification has been proven to reduce heart attacks, strokes, and death. These aren't optional add-ons; they're the core of your treatment.

Third, symptoms can improve dramatically. Whether through medications alone or with the addition of revascularization, most patients achieve good control of their angina and return to their normal activities.

Fourth, prevention never stops. Every day that you maintain a healthy diet, stay physically active, take your medications, and avoid smoking, you're actively slowing the progression of your disease and reducing your risk of a future event.

Fifth, new treatments are coming. The pace of innovation in cardiovascular medicine is faster than at any point in my career. Anti-inflammatory therapies, genetic risk stratification, advanced imaging, and novel drug targets are all expanding our ability to prevent and treat coronary artery disease.

If you have questions about your heart health, or if you've been told you have coronary artery disease and want to understand your options, I encourage you to schedule an evaluation. At San Diego Cardiovascular Associates in Encinitas, I work with each patient to develop a personalized plan that addresses their specific risk factors, anatomy, symptoms, and goals. Together, we can build a strategy that protects your heart for the long term.

References

Stone, Peter H., Peter Libby, and William E. Boden. "Fundamental Pathobiology of Coronary Atherosclerosis and Clinical Implications for Chronic Ischemic Heart Disease Management: The Plaque Hypothesis." JAMA Cardiology 8, no. 2 (2023): 192-201.

Joshi, Parag H., and James A. de Lemos. "Diagnosis and Management of Stable Angina: A Review." JAMA 325, no. 17 (2021): 1765-1778.

Rao, Sunil V., Michelle L. O'Donoghue, Marc Ruel, et al. "2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes." Journal of the American College of Cardiology 85, no. 15 (2025): 1-98.

Virani, Salim S., Lori K. Newby, Suzanne V. Arnold, et al. "2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease." Journal of the American College of Cardiology 82, no. 9 (2023): 833-955.

Gulati, Martha, Phillip D. Levy, Debabrata Mukherjee, et al. "2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain." Journal of the American College of Cardiology 78, no. 22 (2021): e187-e285.

Bhatt, Deepak L., Renato D. Lopes, and Robert A. Harrington. "Diagnosis and Treatment of Acute Coronary Syndromes: A Review." JAMA 327, no. 7 (2022): 662-675.

Ferraro, Riccardo, Joanna M. Latina, Aamir Alfaddagh, et al. "Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm." Journal of the American College of Cardiology 76, no. 19 (2020): 2252-2266.

Nelson, Katherine, Valentin Fuster, and Paul M. Ridker. "Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week." Journal of the American College of Cardiology 82, no. 7 (2023): 648-660.

Ridker, Paul M., Deepak L. Bhatt, Aruna D. Pradhan, et al. "Inflammation and Cholesterol as Predictors of Cardiovascular Events Among Patients Receiving Statin Therapy: A Collaborative Analysis of Three Randomised Trials." Lancet 401, no. 10384 (2023): 1293-1301.

Mechanick, Jeffrey I., Michael E. Farkouh, Jonathan D. Newman, and W. Timothy Garvey. "Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps." Journal of the American College of Cardiology 75, no. 5 (2020): 525-538.

Schunkert, Heribert, Pradeep Natarajan, and Nilesh J. Samani. "The Inherited Basis of Coronary Artery Disease." New England Journal of Medicine 394, no. 11 (2026): 1051-1063.

Lincoff, A. Michael, Kirstine Brown-Frandsen, Helen M. Colhoun, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." New England Journal of Medicine 389, no. 24 (2023): 2221-2232.

Published on damianrasch.com

The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.